Physician profile
Gregory C Beato
NPI 1740312230
$15,251.28
in general payments reported to CMS, 2019-2025
59 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,262 · 2020: $1,581 · 2021: $2,255 · 2022: $2,384 · 2023: $2,253 · 2024: $2,264 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,770.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,707.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,315.90 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,138.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,133.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $923.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $842.48 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $756.39 | 2019-2025 | Evenity, Repatha, Prolia |
| E.R. Squibb & Sons, L.L.C. | $473.39 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $418.01 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.70 | 2019-2025 | Jardiance |
| Mannkind Corporation | $370.88 | 2019-2023 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $317.47 | 2021-2025 | |
| Bausch Health US, LLC | $298.86 | 2019-2023 | Aplenzin |
| Astellas Pharma US INC | $261.55 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $253.18 | 2019-2023 | Xarelto |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Beato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.